You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》德銀首予中生製藥(01177.HK)「買入」評級 目標價6.5元
阿思達克 08-03 10:27
德銀發表評級報告指,中生製藥(01177.HK)擁有多元化的產品組合,相信能緩解中國產品價格壓力的關鍵因素;該行認為,受到研發投資方面的推動下,公司應會繼續推出創新藥品及仿製藥。該行認為,在持續的營運和對科興疫苗的成功投資,為公司帶來充足的資源,這亦將會支持進一步潛在的併購。 該行預計,公司在2021年至24年的收入複合年增長率為12.8%,核心淨利潤(不包括新冠疫苗)複合年增長率為12.7%,並基於公司27倍預期市盈率,較3年平均水平低於1個標準差,給予其目標價為6.5元,以及首予投資評級為「買入」。(ca/k) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account